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Abstract
During adaptive immune response, pathogen-specific CD8
+ T cells recognize preferentially a small number of epitopes, a
phenomenon known as immunodominance. Its biological implications during natural or vaccine-induced immune
responses are still unclear. Earlier, we have shown that during experimental infection, the human intracellular pathogen
Trypanosoma cruzi restricts the repertoire of CD8
+ T cells generating strong immunodominance. We hypothesized that this
phenomenon could be a mechanism used by the parasite to reduce the breath and magnitude of the immune response,
favoring parasitism, and thus that artificially broadening the T cell repertoire could favor the host. Here, we confirmed our
previous observation by showing that CD8
+ T cells of H-2
a infected mice recognized a single epitope of an
immunodominant antigen of the trans-sialidase super-family. In sharp contrast, CD8
+ T cells from mice immunized with
recombinant genetic vaccines (plasmid DNA and adenovirus) expressing this same T. cruzi antigen recognized, in addition
to the immunodominant epitope, two other subdominant epitopes. This unexpected observation allowed us to test the
protective role of the immune response to subdominant epitopes. This was accomplished by genetic vaccination of mice
with mutated genes that did not express a functional immunodominant epitope. We found that these mice developed
immune responses directed solely to the subdominant/cryptic CD8 T cell epitopes and a significant degree of protective
immunity against infection mediated by CD8
+ T cells. We concluded that artificially broadening the T cell repertoire
contributes to host resistance against infection, a finding that has implications for the host-parasite relationship and vaccine
development.
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Introduction
MHC class Ia-restricted CD8
+ T cells are important mediators
of the adaptive immune response against infections caused by
intracellular microorganisms, including the digenetic intracellular
protozoan parasite Trypanosoma cruzi, the causative agent of Chagas
disease (American trypanosomiasis). During experimental infec-
tion, this T cell subpopulation has been shown to be critical for
host survival even when small doses of parasites are used in
challenges [1–5]. In spite of the CD8
+ T-cell mediated immune
response, the parasite survives within the host and establishes a
life-long chronic infection. Parasite persistence is considered one of
the critical factors in the development of the complex immuno-
pathology caused by T. cruzi that may occur years after the initial
infection in ,30% of infected individuals [6–11]. Thus,
understanding how the parasites escape the immune response
and persist for such long periods may help us to find new means
for interventions against Chagas disease that would improve
quality of life for millions of infected individuals in Latin America
Recent studies on the CD8
+ T-cell immune responses that occur
during experimental T. cruzi infection in inbred mouse strains
described a surprising immunodominance of certain epitopes
expressed by members of a large family of T. cruzi surface antigens
named trans-sialidases (TS) [1,5,12–20]. How and why this strong
pattern of immunodominance is established is still a matter of
debate. In general terms, immunodominance can emerge as a
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complex of MHC-I-peptide on the surface of antigen presenting
cells (APC) such as antigen concentration, stability or epitope
availability after processing and translocation to the endoplasmic
reticulum, where the MHC-I-peptide complex is assembled to be
transported to the APC surface [21–24].
After a stable MHC-I-peptide complex is formed on the surface
of the APC, factors related to CD8
+ T cells, such as the frequency
of precursors, their TCR affinities, their capacity to proliferate
in response to antigen and, thus, be incorporated into the pool of
responder cells, are factors that shape immunodominance hierar-
chies. These factors transcend the MHC restriction element and
may create T-cell competition for APCs and other resources,
enabling certain CD8
+ T cells to dominate and suppress others
[23–29].
By comparing the specificity of CD8
+ T cells of homozygous and
heterozygous mouse strains, we observed that the immunodomi-
nance that occurs during experimental T. cruzi infection could be
exerted not only on epitopes restricted by the same MHC molecules
but also, unexpectedly, on the immune response to epitopes
restricted by different MHC-I molecules. This phenomenon,
termed cross-competition, represents a potent means by which T
cells with a certain specificity may become immunodominant [30–
34]. This strong and unusual phenomenon has been shown to be
due to T. cruzi infection because following immunization with
recombinant adenovirus expressing the same parasite antigens, this
pattern of immunodominance was not observed [15].
Based on these observations, we hypothesized that this compe-
tition/immunodomination between T cells of different speci-
ficities could be a sophisticated strategy that T. cruzi developed to
reduce the breath and magnitude of CD8
+ T-cell responses,
suppressing the immune responses of these T cells with other
specificities in order to escape complete elimination by host
effector cells. Thus, we expected that artificially broadening the
immune response to include T cells specific for subdominant or
cryptic epitopes could favor the host, counteracting the restriction
imposed by the infection. Here, we tested this hypothesis by using
mice genetically immunized with a mutated form of the amastigote
surface protein (asp) - 2 gene in which the immunodominant CD8 T
cell epitope is no longer functional. The CD8 T cell-mediated
immune response of these mice was directed only to the newly
described subdominant/cryptic CD8 T cell epitopes of ASP-2.
Even in the absence of an immune response directed to the
immunodominant epitope, these mice displayed a significant
degree of protective immunity, albeit not as strong as the immune
response elicited by the original gene expressing both the
immunodominant and the subdominants epitopes. These results
are compatible with our hypothesis that artificially broadening the
immune response favors the host. Indirectly, we suggest that
immunodominance may in fact be a mechanism to establish a
chronic infection.
Materials and Methods
Ethics Statement
All experimental procedures were approved by the Ethics
Committee for Animal Care of the Federal University of Sa ˜o
Paulo (Id # CEP 0426/09).
Mice and parasites
Female 8-week-old H-2
a mice (B10.A and A/Sn) were
purchased from CEDEME (Federal University of Sa ˜o Paulo).
Bloodstream trypomastigotes of the Y strain of T. cruzi were
obtained from A/Sn mice infected 7–8 days earlier [12]. Each
B10.A or A/Sn mouse was challenged i.p. with a final dose
containing 10
4 or 150 parasites, respectively, in a final volume of
0.2 mL. Parasite development was monitored by counting the
number of bloodstream trypomastigotes in 5 mL of fresh blood
collected from the tail vein [12].
Peptides
Peptides were purchased from Genscript (Piscataway, NJ).
Purity was as follows: TEWETGQI (95%); PETLGHEI (97.4%);
YEIVAGYI (99.40%); TPTAGLVGF (98.6%); GSRNGNDRL
(97.1%); ESKSGDAPL (96.1%); HEHNLFGI (98.7%); ESSTP-
TAGL (99.1%); ESEPKRPNM (98.7%); VSWGEPKSL (99.2%);
YSDGALHLL (97.3%); AESWPSIV (96.5%); and RPNMSRHLF
(99.4%).
Recombinant plasmids and adenoviruses
Plasmid pIgSPCl.9 and the human replication-defective adeno-
virus type 5 containing the asp-2 gene were obtained as described
previously [35,36]. Mutated asp-2 was generated by a series of
PCR reactions using DNA encoding the asp-2 clone 9 gene as a
template (Genbank Accession Number: AY186572). In the first
reaction, the forward and reverse oligonucleotides were as follows:
i) 59-GGGGGTACCATGCTCTCACGTGTTGCT-39;
ii) 59-GAACGATCATGAGTGCTTGGCCCGTCTCC-
CATGCGGTGATGCGGGGATC-39
In the second reaction, they were as follows:
i) 59-GATCCCCGCATCACCGCATGGGAGACGGGA-
CAAGCACTCATGATCGTTC-39
ii) 59-GGGTCTAGATCAGACCATTTTTAGTTCACC-39.
PCR products were purified, mixed and subjected to a third
PCR reaction. Forward and reverse oligonucleotides were
respectively
i) 59-GGGGGTACCATGCTCTCACGTGTTGCT-39;
ii) 59-GGGTCTAGATCAGACCATTTTTAGTTCACC-39.
The final PCR product was completely sequenced. The only
modifications found were in the nucleotide sequences encoding the
immunodominant epitope TEWETGQI. The new sequence
encoded the amino acids (AA) TAWETGQA. This plasmid is
referred to as pIgSpTAWETGQA. The new gene was also
subcloned into the pAdCMV shuttle vector, and the recombinant
replication-defective adenovirus human adenovirus 5 was pro-
duced by Vectors BioLabs, Philadelphia, USA. This new recom-
binant adenovirus is referred to as AdTAWETGQA. Viruses and
plasmids were purified as described previously [35–37]. Mice were
inoculated intra-muscularly (i.m.) in each tibialis anterioris muscle
with 50 mg of plasmid DNA 3 times every 3 weeks.
Heterologous prime-boost immunization consisted of priming
i.m. with a total of 100 mg of plasmid DNA followed by a dose of
viral suspension containing 2610
8 plaque forming units (pfu) of
adenovirus twenty-one days later in the same locations. Immuno-
logical assays or challenges were performed 14 days after viral
inoculation.
In vivo depletion of CD8
+ T cells were performed by treating
vaccinated A/Sn mice with 53.6.7 MAb. At days 2 and 3 before
challenge with trypomastigotes, mice were injected i.p. with a dose
of 1 mg of anti-CD8 or control Rat IgG. Seven days after
challenge, each mouse received one more dose of 1 mg of anti-
CD8 or Rat IgG. The efficacy of depletion of CD8
+ spleen cells
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compared to Rat IgG treated ones.
Immunological T cell assays
Ex vivo ELISPOT (IFN-c)o rin vivo cytotoxic assays were
performed exactly as described previously [12,15]. The surface
mobilization of CD107a and the intracellular expression of
cytokines (IFN-c, TNF-a, IL-2 and IL-10) was evaluated after in
vitro culture of splenocytes in the presence or absence of antigenic
stimulus. Cells were washed three times in plain RPMI and re-
suspended in cell culture medium consisting of RPMI 1640
medium, pH 7.4, supplemented with 10 mM Hepes, 0.2% sodium
bicarbonate, 59 mg/l of penicillin, 133 mg/l of streptomycin, and
10% Hyclone fetal bovine sera (Hyclone, Logan, Utah). The
viability of the cells was evaluated using 0.2% Trypan Blue
exclusion dye to discriminate between live and dead cells. Cell
concentration was adjusted to 5610
6 cells/mL in cell culture
medium containing anti-CD28 (2 mg/mL), Brefeldin A (10 mg/
mL), Monensin (5 mg/mL) and FITC-labeled anti-CD107a (Clone
1D4B, 2 mg/mL, BD Pharmingen). In half of the cultures, a final
concentration of 10 mM of the VNHRFTLV peptide was added.
The cells were cultivated in flat-bottom 96-well plates (Corning) in
a final volume of 200 ml in duplicate, at 37uC in a humid
environment. After a 20-h incubation, cells were stained for
surface markers with Per-CP or PE-labeled anti-CD8 on ice for
20 min. To detect IFN-c, TNF-a? IL-2 and IL-10 by intra-cellular
staining (ICS), cells were then washed twice in buffer containing
PBS, 0.5% BSA and 2 mM EDTA, fixed in 4% PBS-paraformal-
dehyde solution for 10 minutes and permeabilized for 15 minutes
in a PBS, 0.1% BSA, 0.1% saponin solution. After being washed
twice, cells were stained for intracellular markers using APC or
PE-labeled anti-IFN-c (Clone XMG1.2) and? PE- labeled anti-
TNF-a (clone MP6-XT22), APC-labeled anti-IL-2 (clone JES6-
5H4) or APC-labeled anti-IL-10 (JES5-16E3) for 20 minutes on
ice. Finally, cells were washed twice and fixed in 1% PBS-
paraformaldehyde. At least 300,000 cells were acquired on a BD
FacsCanto flow cytometer and then analyzed with FlowJo.
Statistical analysis
Values were expressed as means 6 SD. These values were
compared using one-way ANOVA followed by Tukey’s HSD tests
(http://faculty.vassar.edu/lowry/VassarStats.html). The LogRank
test was used to compare mouse survival rates after challenge with
T. cruzi (http://bioinf.wehi.edu.au/software/russell/logrank/). The
differences were considered significant when the P value was ,0.05.
Results
During experimental infection of H-2
b or H-2
a inbred mouse
strains with parasites of the Y strain of T. cruzi, two epitopes were
identified within the ASP-2 antigen represented by the
VNHRFTLV or TEWETGQI peptides. They were recognized
by H-2K
b- or H-2K
k-restricted CD8
+ cytotoxic T cells, respec-
tively [12,14,15,37,38]. ASP-2 is a member of the large family of
TS surface antigens and is abundantly expressed only in the
intracellular forms (amastigotes) of T. cruzi [39]. Fig. 1A and
Table 1. Peptides used in the study.
Peptide AA positions
Predicted H-2
restriction
TEWETGQI 320–327 K
k
PETLGHEI 650–657 K
k
YEIVAGYI 140–147 K
k
HEHNLFGI 130–137 K
k
AESWPSIV 121–128 K
k
TPTAGLVGF 488–496 L
d
RPNMSRHLF 36–44 L
d
GSRNGNDRL 172–179 L
d
ESKSGDAPL 69–77 L
d
ESEPKRPNM 31–39 L
d
ESSTPTAGL 485–493 L
d
VSWGEPKSL 239–247 L
d
YSDGALHLL 438–446 L
d
Peptides were selected by the scores determined by programs available at the
sites: http://www.syfpeithi.de/and http://www-bimas.cit.nih.gov/molbio/
hla_bind/.
Putative anchor residues are in bold and underlined.
doi:10.1371/journal.pone.0022011.t001
Figure 1. Structure and localization of Amastigote Surface Protein-2 (ASP-2). A- Schematic view of the primary structure of T. cruzi ASP-2.
B- HeLa cells were infected for 48 h with trypomastigotes of the Y strain. After fixation, indirect immunofluorescence or DAPI staining were performed
as described using MAb K22 and imaged using fluorescence microscopy [39]. Bar, 14 mM.
doi:10.1371/journal.pone.0022011.g001
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antigen and its expression by amastigotes.
To test whether the H-2K
k-restricted epitope TEWETGQI
could be an immunodominant epitope, a series of synthetic
peptides containing the predicted AA anchor motif for binding to
the H-2K
k or H-2L
d alleles of mouse MHC haplotype H-2
a was
employed. No epitope was predicted to bind to H-2D
d (Table 1).
After infection of H-2
a mice, antigen-specific IFN-c producing
cells could only be detected in the presence of the peptide
TEWETGQI (Fig. 2A). We concluded that this epitope was the
immunodominant epitope of ASP-2 during infection of H-2
a mice
with the Y strain of T. cruzi. H-2
a mice used in this experiment
were B10.A because they are resistant to infection with T. cruzi.
We showed previously that the strong pattern of immunodo-
minance observed following infection with T. cruzi was not
duplicated in mice genetically immunized with a recombinant
adenovirus expressing ASP-2 (AdASP-2, ref. 15). Then, we
determined whether genetically immunized H-2
a mice could
present a different pattern of immunodominance. We used a
genetic immunization approach which consisted of a heterologous
prime-boost regimen using plasmid DNA followed by a recom-
binant adenovirus both containing the same asp-2 gene. This
protocol provided strong and long lasting protective immunity
against experimental infection mediated by CD8
+ T cells [37,38].
In these experiments, we used H-2
a mice of the A/Sn strain. These
mice are highly susceptible to infection with T. cruzi, allowing us to
perform protective immunity studies [37,38]. Nevertheless, it is
important to mention that the results were similar when we used
B10.A mice.
After ex vivo stimulation with our synthetic peptides, as expected,
IFN-c producing cells were detected following stimulation with the
TEWETGQI peptide. In addition to this epitope, two other
epitopes (PETLGHEI and YEIVAGYI) induced IFN-c produc-
tion by immune cells (Fig. 2A). These peptide-specific IFN-c
producing cells were CD8
+ T cells as determined by simultaneous
staining of intra-cellular IFN-c and the surface marker CD8 (see
below).
These peptides were recognized by cytotoxic cells in H-2
a mice
as determined by in vivo cytotoxicity assays using target cells coated
with each of these peptides. B10.A mice infected with T. cruzi
developed strong in vivo cytotoxicity against target cells coated with
the peptide TEWETGQI. In contrast, very limited (if any) in vivo
cytotoxicity was observed against target cells coated with peptides
PETLGHEI and YEIVAGYI. These results were not due to
different kinetics of the immune response because we observed the
same results 14 or 28 days after an infectious challenge (Fig. 2B).
However, A/Sn (H-2
a) mice genetically vaccinated with a
heterologous prime-boost vaccination regimen displayed easily
detectable in vivo cytotoxic activity against target cells coated with
any of these three peptides. The elimination of target cells coated
with peptide TEWETGQI was always stronger than the two
others, suggesting a pattern of immunodominance.
To determine whether other cytokines and/or effector mole-
cules could be secreted by peptide-specific T cells, we performed
staining to detect surface mobilization of CD107a (a marker for
exocytosis) or intra-cellular accumulation of IFN-c, TNF-a, IL-2
Figure 2. CD8 T-cell epitope identification during immune
responses of H-2
a mice infected with T. cruzi or genetically
vaccinated with asp-2 gene. B10.A mice were infected with 10
4 T.
cruzi blood parasites. A/S mice were immunized with pIgSPCl.9 followed
by AdASP-2 and injected i.m. at 0 and 3 weeks, respectively. Control
mice were naı ¨ve or injected with pcDNA3 followed by pcDNA3/Adb-gal.
A- Two weeks after infection or the final immunizing dose, splenic cells
were re-stimulated in vitro in the presence of medium or the indicated
peptides at a final concentration of 10 mM. The number of splenic IFN-c
spot-forming cells (SFC) was estimated by ex vivo ELISPOT assay. B- In
vivo cytotoxic activity was estimated by injecting each mouse with
syngeneic CFSE-labeled splenic cells coated with or without 2 mM of the
indicated peptide. Results are expressed as means 6 SD of 4 mice per
group and are representative of experiments performed at least twice
with similar results. Asterisks denote that the number of SFC or in vivo
cytotoxicity were significantly higher when compared to naı ¨ve or
pcDNA3/Adb-gal injected mice (P,0.01, one-way ANOVA).
doi:10.1371/journal.pone.0022011.g002
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+ T cells from B10.A mice
infected with T. cruzi or A/Sn mice immunized with pIgSCl.9/AdASP-2 vaccine. B10.A or A/Sn mice were infected or immunized as described
in the legend of Fig. 2. Control mice were either naive mice or mice immunized with pCDNA3/Adb-gal. Twenty one or fourteen days after infection or
immunization, respectively, these mice had their splenic cells cultured in the presence of anti-CD107a and anti-CD28, with or without the peptides
TEWETGQI, PETLGHEI or YEIVAGYI. After 12 h, cells were stained for CD8, IFN-c, TNF-a, IL-2 and IL-10. Representative analyses (medians) are shown
from four mice performed per experiment. A) Example of splenic CD8
+ cells from B10.A naive mice cultivated in vitro in the presence of medium
alone (Medium) or with the indicated peptides and stained for expression of IFN-c and TNF-a. B, C and D) Examples of splenic CD8
+ cells from B10.A
infected mice cultivated in vitro in the presence of medium alone (Medium) or with the indicated peptides and stained for expression of: B) IFN-c and
TNF-a; C) IFN-c and IL-2; D) IFN-c and IL-10. E and F) Examples of splenic CD8
+ cells from mice immunized with pcDNA3/Adb-gal cultivated in vitro in
the presence of medium alone (Medium) or with the indicated peptides and stained for surface mobilization of CD107a and expression IFN-c (panel
E) or expression of IFN-c and TNF-a (panel F). G and H) Examples of splenic CD8
+ cells from mice immunized with pIgSPCl.9/AdASP-2 cultivated in
Immunity to Subdominant/Cryptic Epitopes
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with T. cruzi, we observed that upon stimulation with TE-
WETGQI, a large fraction of CD8
+ cells mobilize CD107a to the
surface (data not shown) and accumulate intra-cellular IFN-c and
TNF-a (Fig. 3B). These CD8
+ cells were therefore multifunctional
CD107a
+IFN-c
+TNF-a
+ (,35%) or IFN-c
+TNF-a
+ (,40%). We
were unable to detect the presence of significant numbers of IL-2
or IL-10 expressing cells in these same samples (Fig. 3C and 3D).
The expression of these cytokines was dependent on the infection
because they were not detected in cells from naive mice (Fig. 3A).
In contrast, a relatively low frequency of CD8
+ splenic cells
stimulated with peptides PETLGHEI or YEIVAGYI mobilized
CD107a to the surface (data not shown) or accumulated intra-
cellular IFN-c or TNF-a (Fig. 3B). We were also unable to detect
the presence of significant numbers of IL-2 or IL-10 expressing
cells in these same cells (Fig. 3C and 3D).
Splenic cells from A/Sn mice genetically vaccinated with
heterologous prime-boost regimen were stimulated with peptides
TEWETGQI, PETLGHEI or YEIVAGYI. The results shows that
a large fraction of the CD8
+ cells of pIgSPCl.9/AdASP-2
immunized mice at the same time mobilize CD107a to the
surface and expressed intra-cellular IFN-c and TNF-a (Fig. 3G to
3J). These cells were therefore multifunctional CD8
+ T cells as we
have previously described [37]. We were unable to detect the
presence of intra-cellular IL-2 or IL-10 in these same cells (data
not shown). These results confirmed and extended the ones
described in Fig. 2).
The description of these two new epitopes allowed us to test
whether immunity to the subdominant/cryptic epitope could
participate during protective immunity against T. cruzi infection, a
phenomenon that has not previously been tested experimentally.
For this purpose, we generated a plasmid DNA and a recombinant
adenovirus containing a mutated form of the asp-2 gene in which
we modified the nucleotides encoding the anchor residues required
for the immunodominant TEWETGQI epitope to bind to the H-
2K
k molecule. The mutated gene expressed the AA sequence
TAWETGQA, where the alanines (A) replaced glutamic acid (E)
or isoleucine (I) of the original epitope. In preliminary experi-
ments, we observed that the synthetic peptide TAWETGQA was
not recognized by immune cells from genetically vaccinated H-2
a
mice (data not shown). Details of the plasmid and recombinant
adenovirus containing the mutated form of the asp-2 gene are
shown in Table 2.
Initially, we genetically immunized mice with plasmids
containing the original gene (pIgSPCl.9), the mutated gene
(pIgSPTAWETGQA) or both plasmids simultaneously. Immune
responses were estimated by ELISPOT after ex vivo stimulation
with the immunodominant epitope TEWETGQI or with the
subdominant/cryptic epitopes PETLGHEI or YEIVAGYI two
weeks after challenge with T. cruzi. We chose this protocol because,
as the immune response following plasmid DNA vaccination is
usually low, it is easier to detect the anamnestic immune responses
after challenge [12]. We observed that all mice immunized with
asp-2 genes (mutated or not) presented specific IFN-c producing
cells when stimulated with subdominant/cryptic epitopes (PETL-
GHEI or YEIVAGYI, Fig. 4A). The immune response was
specific because mice immunized with control plasmid pcDNA3
failed to recognize these peptides. However, we detected IFN-c
producing cells specific to TEWETGQI only in mice immunized
with plasmid pIgSPCl.9. It is noteworthy that the number of cells
detected in mice immunized with pIgSPTAWETGQA was similar
to the number of cells in pcDNA3 injected mice (Fig. 4A). These
numbers reflect cells primed during infection. Analysis of in vivo
cytotoxic activity also demonstrated that in mice immunized with
the plasmid pIgSPTAWETGQA, the response to the immunodo-
minant epitope TEWETGQI was not different from control mice
immunized with pcDNA3 (Fig. 4B). These immunological analyses
demonstrated that mice immunized with pIgSPTAWETGQA
indeed lost the functional immunodominant TEWETGQI
response but had an unaltered ability to elicit immune responses
to the subdominant epitopes PETLGHEI and YEIVAGYI.
After challenge, mice immunized with plasmids containing the
asp-2 gene (mutated or not) presented significantly lower
parasitemia than control mice immunized with pcDNA3
(Fig. 4C). Although the levels of parasitemia were not statistically
different when compared to mice vaccinated with the plasmid
containing the mutated asp-2 gene, the mortality of these animals
was significantly faster (Fig. 4D). We therefore concluded that
broadening the CD8
+ T cell immune response by vaccination with
a plasmid containing epitopes that elicit immune responses to
subdominant/cryptic epitopes of ASP-2 could provide some
degree of protective immunity. Nevertheless, because protective
immunity elicited by vaccination with pIgSPTAWETGQA was
not as efficient, the presence of a functional immunodominant
epitope was clearly important for effective protective immunity.
We then sought to test the same hypotheses described above
using a distinct approach. For that purpose, H-2
a mice were
primed with plasmid pIgSPCl.9 followed by a booster immuniza-
tion with AdASP-2 (heterologous prime- boost regimen). Alterna-
tively, mice were primed with plasmid pIgTAWETGQA followed
by a booster immunization with AdTAWETGQA. We consider
this approach complementary to the one described above because
plasmid or adenovirus may used distinct routes for stimulating
CD8
+ T cells.
Immune responses were estimated 14 days after the booster
immunization by ELISPOT following ex vivo stimulation with
synthetic peptides encoding the immunodominant epitope TE-
WETGQI, the subdominant/cryptic epitopes PETLGHEI or
YEIVAGYI or the mutated epitope TAWETGQA. We chose this
protocol because the immune responses following heterologous
prime boost immunization generates strong immune responses
that can be easily detected after boosting [37]. We observed that
mice immunized with asp-2 genes (mutated or not) had specific
IFN-c producing cells when stimulated with peptides PELTHGEI
or YEIVAGYI. The fact that these responses were of similar
magnitude strongly argued that the expression/immunogenicity of
vitro in the presence of medium alone (Medium) or with the indicated peptides and stained for surface mobilization of CD107a and expression IFN-c
(panel G) and expression IFN-c and TNF-a (panel H). I and J) Determination of multifunctional CD8
+ cells from mice immunized with pIgSPCl.9/
AdASP-2 cultivated in vitro in the presence of the indicated peptides and stained for surface mobilization of CD107a and expression IFN-c and TNF-a.
doi:10.1371/journal.pone.0022011.g003
Table 2. Genetic vectors used in the study.
Designation Vector ASP-2 CD8 epitopes
pIgSPCl.9 Plasmid TEWETGQI PETLGHEI YEIVAGYI
pIgSPTAWETGQA.9 Plasmid TAWETGQA PETLGHEI YEIVAGYI
AdASP-2 Adenovirus TEWETGQI PETLGHEI YEIVAGYI
AdTAWETGQA Adenovirus TAWETGQA PETLGHEI YEIVAGYI
doi:10.1371/journal.pone.0022011.t002
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producing cells specific for the TEWETGQI epitope only in mice
immunized with pIgSPCl.9/AdASP-2. In contrast, none of the
immunized mice presented IFN-c producing cells when stimulated
with the TAWETGQA peptide (Fig. 5A). The analysis of in vivo
cytotoxic activity showed a similar picture (Fig. 5B). We also
performed intra-cellular cytokine staining analysis for IFN-c and
TNF-a after in vitro peptide stimulation. As depicted in Fig. 5C, we
detected CD8
+ cells expressing IFN-c and/or TNF-a specific for
the TEWETGQI epitope only in mice immunized with
pIgSPCl.9/AdASP-2 (Fig. 5C). Similar analyses performed 14
days after an infectious challenge with T. cruzi exhibited the same
Figure 4. CD8 immune responses and trypomastigote-induced parasitemia and mortality in A/Sn mice genetically immunized with
different plasmid DNA containing the asp-2 gene. A/Sn mice were immunized with pcDNA3, pIgSPCl.9, pIgSPTAWETGQA or simultaneously
with the last two (pIgSPCl.9 and pIgSPTAWETGQA). Immunization consisted of 3 doses of 100 mg of DNA each given by the i.m. route in the tibialis
anterioris three weeks apart. A- Two weeks after the final immunizing dose, mice were challenged i.p. with 150 bloodstream trypomastigotes. Two
weeks after infection, splenic cells were re-stimulated in vitro in the presence of medium only or the indicated peptides at a final concentration of
10 mM. The number of splenic IFN-c spot-forming cells (SFC) was estimated by ex vivo ELISPOT assay. B- In vivo cytotoxic activity was estimated by
injecting each mouse with syngeneic CFSE-labeled splenic cells coated with or without 2 mM of the indicated peptide. Results are expressed as means
6 SD of 4 mice per group and are representative of experiments performed at least twice with similar results. Asterisks denote that the number of
SFC, or the in vivo cytotoxicity, were significantly higher when compared to SFC found in naı ¨ve or pcDNA3/Adb-gal-injected mice (P,0.01). C-
Parasitemia for each mouse group is represented as mean 6 SD (n=5–7). Asterisks denote that mice from groups immunized with pIgSPCl.9 or
pIgSPTAWETGQA or both had significantly lower parasitemia (P,0.01) than animals injected with pcDNA3. The curves of parasitemia of animals
immunized with pIgSPCl.9 (squares) or pIgSPTAWETGQA (triangles) are superimposed. D- Kaplan-Meier curves for the survival of mouse groups
immunized and challenged as described above (n=5–7). Mice from groups immunized with pIgSPCl.9 or pIgSPCl.9/pIgSPTAWETGQA survived
significantly longer than animals injected with pcDNA3 or pIgSPTAWETGQA (P,0.05, in all cases, LogRank test). Mice immunized with
pIgSPTAWETGQA also survived longer than animals injected with pcDNA3 (P,0.05). No animals died after the 30
th day until they were euthanized.
Results are representative of two independent experiments.
doi:10.1371/journal.pone.0022011.g004
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logical analyses demonstrated that heterologous prime-boost
immunization with pIgSPTAWETGQA/AdTAEWTGQA failed
to induce an immune response to the immunodominant epitope
TEWETGQI but induced almost unaltered immune responses to
the subdominant epitopes PETLGHEI or YEIVAGYI.
After challenge, parasitemia in mice immunized with the asp-2
genes (mutated or not) was significantly lower than in control
mice injected with pcDNA3/Adb-gal (P,0.01, Fig. 6A). Although
most of the mice immunized with pIgSPTAWETGQA/Ad-
TAEWTGQA died after challenge, they survived longer than
control mice injected with pcDNA3/Adb-gal (Fig. 6B, P,0.01,
LogRank test). In parallel, vaccinated and control mice were
challenged by the s.c. route. We observed that the majority of the
mice immunized with pIgSPTAWETGQA/AdTAEWTGQA
survived the infectious challenge (Fig. 6D). We therefore conclu-
Figure 5. CD8 immune responses in A/Sn mice immunized with asp-2 using the heterologous DNA prime-adenovirus boost
vaccination regimen. A/Sn mice were primed i.m. with 100 mg of plasmids pcDNA3, pIgSPCl.9 or pIgSPTAWETGQA. Three weeks later, these mice
were boosted i.m. with 2610
8 pfu Adb-gal, AdASP-2 or AdTAWETGQA. A- Two weeks after the last dose, splenic cells were re-stimulated in vitro in the
presence of medium only or the indicated peptides at a final concentration of 10 mM. The number of splenic IFN-c spot forming cells (SFC) was
estimated by ex vivo ELISPOT assay. B- In vivo cytotoxic activity was estimated by injecting each mouse with syngeneic CFSE-labeled splenic cells
coated with or without 2 mM of the indicated peptide. Results are expressed as mean 6 SD of 4 mice per group and are representative of
experiments performed at least twice with similar results. Asterisks denote that the number of SFC or in vivo cytotoxicity were significantly higher
when compared to SFC found in naı ¨ve or pcDNA3/Adb-gal injected mice (P,0.01). C- Fourteen days after the last dose, these mice had their splenic
cells cultured in the presence of anti-CD28 and Medium or the indicated peptides. After 12 h, cells were stained for CD8, IFN-c and TNF-a. Examples
of splenic CD8
+ cells from immunized mice. Representative analyses (medians) are shown from four mice performed per experiment.
doi:10.1371/journal.pone.0022011.g005
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vaccination that elicits immune responses to subdominant/cryptic
epitopes of ASP-2 provides protective immunity against infection.
Nevertheless, likewise in the case of the plasmid DNA, after an i.p.
challenge, in terms of survival, immunization with only genes
expressing subdominant epitopes was not as effective as immuni-
zation with genes expressing both the dominant and the
subdominant epitopes.
Finally, to firmly establish that protective immunity was
mediated by CD8
+ T cells, we performed in vivo depletion experi-
ments in mice vaccinated with the pIgSPCl.9/AdASP-2 or
pIgSPTAWETGQA/AdTAEWTGQA. Treatment with anti-
CD8 MAb renders these mice more susceptible to infection.
CD8 depleted mice presented higher parasitemia (Fig. 7A and B)
and shorter survival times (Fig. 7C and D) when compared to A/
Sn mice vaccinated with heterologous prime-boost regimen
(pIgSPCl.9/AdASP-2 or pIgSPTAWETGQA/AdTAEWTGQA)
and treated with rat IgG. CD8 depleted mice had their survival
time reduced to the same time as control mice which were injected
with pcDNA3/Adb-gal.
Discussion
Here, we initially confirmed and extended our previous
observation that experimental infection with the human intracel-
lular pathogen T. cruzi restricted the repertoire of CD8
+ T cells.
While immune cells of infected H-2
a mice recognized a single
immunodominant epitope of ASP-2, cells from mice immunized
with recombinant genetic vaccines expressing this same T. cruzi
antigen recognized, in addition to the immunodominant epitope,
two other subdominant/cryptic epitopes. The sub-dominant
epitopes not only failed to elicit IFN-c and in vivo cytotoxicity
Figure 6. Trypomastigote-induced parasitemia and mortality in A/Sn mice immunized with asp-2 using the heterologous DNA
prime-adenovirus boost vaccination regimen. A/Sn mice were immunized as depicted in the legend of Fig. 5. Two weeks after the final
immunizing dose, mice were challenged i.p. (Panels A and B) or s.c. (Panels C and D) with 150 bloodstream trypomastigotes. Parasitemia for each
mouse group is represented as mean 6 SD (n=10 or 11). Asterisks denote that mice from groups immunized with pIgSPCl.9/AdASP-2 or
pIgSPTAWETGQA/AdTAWTEGQA had significantly lower parasitemia (P,0.01) than pcDNA3/Adb-gal-injected animals. Panels B and D represent
Kaplan-Meier curves for survival of the mouse groups immunized and challenged as described above (n=10 or 11). Mice immunized with pIgSPCl.9/
AdASP-2 survived significantly longer than animals immunized with pIgSPTAWETGQA/AdTAWETGQA or pcDNA3/Adb-gal (P=0.01 or P,0.01,
respectively). Mice immunized with pIgSPTAWETGQA/AdTAWETGQA survived significantly longer than pcDNA3/Adb-gal-injected animals (P,0.01).
Results are representative of two pooled experiments. No animals died after the 40
th day.
doi:10.1371/journal.pone.0022011.g006
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or IL-10 secretion by CD8
+ T cells (Fig. 3). The precise reason for
this strong immunodominant pattern during T. cruzi infection is
unknown at present. One possible explanation for this biased
immune response could be to provide an advantage to the parasite
by avoiding an even higher and broader immune response. This
hypothesis is in agreement with earlier studies showing that
immunity to subdominant epitopes can provide an important
contribution to protective immunity against viral infection [34,40–
43]. Our results also corroborated this hypothesis. Immunity to
epitopes that are not commonly recognized during infection
(cryptic) provided a significant degree of protective immunity.
Nonetheless, immune responses against these cryptic epitopes did
not substitute completely for CD8
+ T cells specific for the
immunodominant TEWETGQI epitope. We observed that
immunization with plasmids alone or in combination with a
recombinant adenovirus that did not express the immunodominant
epitope elicited immune responses to the subdominant/cryptic
epitopes but failed to provide optimal protective immunity when
compared to a plasmid that expresses both the immunodominant
and subdominants epitopes (Fig. 4D, 6B and 7D). These results
demonstrate that the response to the immunodominant epitope
contributes to the immunity elicited by genetic vaccination and is
might be required for highly efficient resistance.
In previous studies, we showed that immunization with short
proteins in the presence of the TLR9 agonist CpG elicited CD8
+
Figure 7. CD8 T cell dependence of protective immunity of A/Sn mice immunized with asp-2 using the heterologous DNA prime-
adenovirus boost vaccination regimen. A/Sn mice were immunized as described in the legend of Fig. 5. pIgSPTAWETGQA/AdTAWTEGQA had
significantly lower parasitemia (P,0.01) than pcDNA3/Adb-gal-injected animals. Before and after challenge, mice were treated as described in
Methods section with rat IgG (control) or anti-CD8 MAb. The parasitemia for each mouse group is represented as mean 6 SD (n=6). Asterisks denote
that mice from groups immunized with pIgSPCl.9/AdASP-2 or pIgSPTAWETGQA/AdTAWTEGQA and treated with Rat IgG had significantly lower
parasitemia (P,0.01) than vaccinated mice treated with anti-CD8 (Panels A and B). Panels C and D represent Kaplan-Meier curves for survival of the
mouse groups immunized and challenged as described above (n=6). Mice immunized with pIgSPCl.9/AdASP-2 or pIgSPTAWETGQA/AdTAWETGQA
and treated with Rat IgG survived significantly longer than vaccinated animals treated with anti-CD8 (P,0.01 in both cases).
doi:10.1371/journal.pone.0022011.g007
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[44]. These short proteins contained only the AA 261 to 500 or
261 to 380. In both cases, they did not express the subdominant/
cryptic epitopes. Based on that, we concluded that immunization
with the immundominant CD8 epitope alone could provide a high
degree of protective immunity even in the absence of the
subdominant epitopes [44]. The fact that the immune response
directed solely to the immunodominant epitope can provide
significant degree of protective immunity against protozoan
parasites has been established a long time ago by the use of
adoptively transferred T cell clones or heterelogous-prime boost
vaccination regimen [45–49].
In earlier studies in which we depleted CD8
+ T cells from
genetically vaccinated mice, we observed that these mice were
unable to control parasitemia and died at the same time as control
unvaccinated animals [37]. Therefore, although genetic immuni-
zation elicits effector CD4
+ T cells, these cells do not account for the
protectionwe observed.Thisconcept wasfurthercorroborated with
experiments of CD8 T cell-depletion performed here (Fig. 7A to D).
Using a different approach, a similar conclusion was also reached
by Rosemberg et al., 2010 [17]. In their study, they induced
simultaneous tolerance to two immunodominant T. cruzi epitopes in
a resistant mouse strain. Following infection, an increased
susceptibility to infection was observed. Nevertheless, they were
still able to control and survive the experimental infection. This
protective immunity was possibly mediated by CD8
+ T cells specific
to subdominant epitopes that substituted for the immunodominant
ones. The AA sequences of these subdominant/cryptic epitopes
have yet to be identified. Together with our study, they strongly
support the notion that the immune responses to both dominant
and subdominant/cryptic epitopes can be important for controlling
experimentalT.cruzi infectionininbredmousestrains.Theseresults
are in agreement with the observation with other parasites such as
Plasmodium. Tolerance to or removal of the the immunodominant
CD8 epitope of P. yoelii led to the development of immunity to CD8
subdominant epitopes as well [50,51].
The mechanism operating during T. cruzi infection to restrict
the immune response leading to immunodominance has yet to be
characterized. We provide initial evidence that it could be
explained by T cell competition for APCs by showing that in
mice infected simultaneously with two different parasite strains
containing different immunodominant epitopes, we could generate
maximal responses to both epitopes without immunodominance or
competition [15]. Our interpretation was that if the epitopes are
presented by different APCs, then the immunodominant pattern is
disrupted. However, a more formal demonstration using bone
marrow chimeric mice studies is lacking. At the molecular level,
this strong immunodominance can be explained by the type of
antigen presentation that predominates during T. cruzi infection.
In recent studies, important evidence has been provided that
subdominant epitopes can only be directly presented by the
expressing cells, which might occur in the case of the recombinant
adenovirus. However, during indirect priming (cross-priming),
these epitopes would be at a disadvantage [52]. T. cruzi may use
cross-priming as the dominant route, drastically reducing the
priming of subdominant epitopes.
In addition to shedding some light on the host-parasite
relationship, our results may have important implications for the
development of T cell vaccines against parasitic diseases. In our
earlier studies, we observed that genetic vaccination with a
heterologous prime-boost regimen employing plasmid DNA and
recombinant adenovirus elicited strong, long lasting CD8
+ Tc e l l -
mediated protective immunity against experimental infection in a
mouse strainhighlysusceptibleto T.cruzi infection [37,38].Here, we
demonstrated that the CD8 T cell-mediated protective immunity
observed was directed to three distinct epitopes, two of which are
cryptic. The strategy of redirecting immunity to epitopes that are not
usually targets of the naturally acquired immune response has been
proposed as a possible means to improve immunity against viral
infection [40–43]. Recently, this strategy was also proven useful to
improve vaccination against T. cruzi infection [53].
Finally, our observations may have important implications
regarding the basis for the strong immunodominance pattern
observed after experimental infection with other intracellular
parasites such as Plasmodium, Toxoplasma gondii and Theileria parva
[50,51,54-57].
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